IPSS-R (Revised International Prognostic Scoring System for MDS)
Stratifies prognosis in newly diagnosed, untreated primary adult myelodysplastic syndrome from cytogenetic risk group, marrow blasts, hemoglobin, platelets, and ANC, assigning a risk category with expected survival; the lab-classified cytogenetic group must be entered — it does not interpret a karyotype.